Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

A distinctive pattern of inflammatory proteins in the blood of adults with celiac disease reflects the severity of gut damage and may offer a noninvasive way to monitor disease activity.

Patients with Crohn's disease in remission who switch from reference ustekinumab to biosimilar versions maintain similar clinical success rates over 6 months to those continuing reference treatment.

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.